Sec Form 13G Filing - ARENA PHARMACEUTICALS INC (ARNA) filing for Longboard Pharmaceuticals Inc. (LBPH) - 2022-03-10

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. __)

Longboard Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock, par value $0.0001 per share
(Title of Class of Securities)

54300N103
(CUSIP Number)

December 31, 2021
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|_| Rule 13d-1(b)
|_| Rule 13d-1(c)
|X| Rule 13d-1(d)



CUSIP No.
54300N103
SCHEDULE 13G
Page
2
of
4
1
Name Of Reporting Persons
Arena Pharmaceuticals, Inc.
2
Check The Appropriate Box If A Member Of A Group (See Instructions)
(a) |_|
(b) |_|
3
SEC Use Only
4
Citizenship Or Place Of Organization
Delaware

Number of
Shares
Beneficially
Owned By
Each
Reporting
Person With
5
Sole Voting Power
3,978,540
6
Shared Voting Power
0
7
Sole Dispositive Power
3,978,540
8
Shared Dispositive Power
0

9
Aggregate Amount Beneficially Owned By Each Reporting Person
3,978,540
10
Check If The Aggregate Amount In Row (9) Excludes Certain Shares
|_|
11
Percent Of Class Represented By Amount In Row 9
23.1%1
12
Type Of Reporting Person (See Instructions)
CO


1 The percentage is calculated based on 17,215,350 shares of Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 4, 2021.

CUSIP No.
54300N103
SCHEDULE 13G
Page
3
of
4

Item 1
(a).
Name of Issuer: Longboard Pharmaceuticals, Inc.
Item 1
(b).
Address of Issuer's Principal Executive Offices: 4275 Executive Square, Suite 950, La Jolla, California 92037
Item 2
(a).
Name of Person Filing: Arena Pharmaceuticals, Inc.
Item 2
(b).
Address of Principal Business Office: 136 Heber Avenue, Suite 204, Park City, Utah 84060
Item 2
(c).
Citizenship: Delaware
Item 2
(d).
Title of Class of Securities: Common Stock, par value $0.0001 per share (“Common Stock”)
Item 2
(e).
CUSIP Number: 54300N103
Item 3.
Not Applicable
Item 4.
Ownership.
(a)
Amount beneficially owned: 3,978,540
(b)
Percent of Class: 23.1%
(c)
Number of shares as to which such person has:
(i)
Sole power to vote or to direct the vote: 3,978,540
(ii)
Shared power to vote or to direct the vote: 0
(iii)
Sole power to dispose or to direct the disposition of: 3,978,540
(iv)
Shared power to dispose or to direct the disposition of: 0
Item 5.
Ownership of Five Percent or Less of a Class: Not Applicable
Item 6.
Ownership of More than Five Percent on Behalf of Another Person: Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: Not Applicable
Item 8.
Identification and Classification of Members of the Group: Not Applicable

CUSIP No.
54300N103
SCHEDULE 13G
Page
4
of
4
Item 9.
Notice of Dissolution of Group: Not Applicable
Item 10.
Certification: Not Applicable


SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

Dated: March 10, 2022

ARENA PHARMACEUTICALS, INC.
B y: /s/ Amit D. Munshi
Name: Amit D. Munshi
Title: President and Chief Executive Officer